Encinitas, California--(June 6, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced the closing of an underwritten public offering for gross proceeds of approximately $6.3 million, which includes full exercise of the...
Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering
Encinitas, California--(June 2, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced the pricing of an underwritten public offering for gross proceeds of approximately $5.5 million prior to deducting underwriting discounts and...
Kiora Pharmaceuticals Reports First Quarter Results; Positive Clinical Data Driving Significant Progress Advancing Pipeline of Eye Disease Treatments
Encinitas, California--(May 9, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) announced its first quarter 2023 results, during which time it significantly advanced its ocular drug development pipeline of clinical-stage candidates for the treatment of Retinitis...
Kiora Pharmaceuticals Presents Encore Imaging Results of KIO-301 for Retinitis Pigmentosa at ASNR 2023 Meeting
Encinitas, California--(May 1, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) announced today an encore presentation on KIO-301 neuroimaging results at The American Society of Neuroradiology 2023 Meeting in Chicago. The late-breaking abstract presentation titled...
Kiora’s Investigational Treatment for Retinitis Pigmentosa, KIO-301, Demonstrates Visual Function Restoration in Patients Who Are Blind
Encinitas, California--(April 27, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) presented preliminary results from an ongoing clinical trial showing its investigational drug, KIO-301, has the potential to restore light perception in patients who are blind or living...
Kiora Pharmaceuticals’ KIO-201 Heals Wounds in Phase 2 Trial of Patients with Persistent Corneal Epithelial Defects
In a second presentation, Kiora shared additional positive results for its KIO-100 platform in the treatment of autoimmune uveitis.Encinitas, California--(April 26, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) presented results of a Phase 2 clinical trial for KIO-201...
Inherited Retinal Disease Expert, Mark Pennesi, M.D., Ph.D., Joins Kiora Pharmaceuticals’ Scientific Advisory Board
Encinitas, California--(April 21, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) has appointed Mark Pennesi, M.D., Ph.D., the Kenneth C. Swan Endowed Professor in Ophthalmology and Molecular and Medical Genetics and the Chief of the Paul H. Casey Ophthalmic Genetics...
Kiora Pharmaceuticals Initiates Phase 2 Trial of KIO-101 for the Treatment of Ocular Presentation of Autoimmune Diseases
Encinitas, California--(April 17, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) enrolled the first patient in its Phase 2 trial of KIO-101 in the treatment of the Ocular Presentations of Rheumatoid Arthritis and other autoimmune diseases (OPRA+). This clinical trial is...
Kiora Announces the Acceptance of Late-Breaking Abstract on Phase 1b Study of KIO-301 in Retinitis Pigmentosa at The American Society of Neuroradiology 2023 Meeting
Encinitas, California--(March 30, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced its late-breaking abstract detailing functional Magnetic Resonance Imaging (fMRI) results from the ABACUS Phase 1b study of KIO-301 in patients...
Kiora Pharmaceuticals Reports 2022 Financial Results; Provides Update on Clinical Development Progress
Encinitas, California--(March 23, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today is providing a business update and reporting financial results for the year ended December 31, 2022.CEO Commentary: "In 2022, we advanced our...